According to a recent LinkedIn post from SpinaFX Medical Inc, the company plans to attend the 29th Annual American Society of Spine Radiology Meeting in New Orleans from Feb. 26–28, 2026. The post notes that senior leaders including the Chief Medical Officer, Chief Strategy Officer, and Head of Clinical Affairs intend to be on-site to discuss the firm’s minimally invasive, image-guided spine therapy, which the post says has received FDA Breakthrough Device designation.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post also points to a hands-on workshop on Feb. 25, 2026, to be led by an external physician, suggesting an emphasis on clinician training and early adopter engagement. For investors, participation in a specialized radiology meeting and highlighting Breakthrough Device status may indicate efforts to build clinical credibility, advance physician awareness, and position the technology for future commercialization, though no specific regulatory, funding, or revenue milestones are mentioned in the post.